Lilly's Trulicity Shows Unique Cardiovascular Outcomes Benefit, Albeit A Modest One
At the ADA annual meeting, Lilly reported positive results from REWIND, a cardiovascular outcomes trial studying the GLP-1 agonist Trulicity in a broad population of patients with and without established CV disease.
You may also be interested in...
Lilly argues the overall trend is positive, although the second quarter was down. Trial successes with Verzenio, Trulicity, Jardiance and mirikizumab offer additional growth potential.
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.